Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine

被引：0
|
作者：
Hauber, B
Candrilli, S
Snyder, EH
McBurney, CR
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Res Triangle Inst, Chapel Hill, NC USA
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
10.1016/S0197-4580(04)80457-3
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [21] Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains
    Erkinjuntt, T
    Skoog, I
    Lane, R
    Andrews, C
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (09) : 756 - 760
  • [22] Long term survival of patients with Alzheimer's disease with and without cerebrovascular disease treated with galantamine
    Feldman, H
    Everitt, B
    Van Baelen, B
    Kavanagh, S
    Brashear, H
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S284 - S284
  • [23] Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis
    Farlow, MR
    Small, GW
    Quarg, P
    Krause, A
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 20 (2-3) : 192 - 197
  • [24] Musical long-term memory throughout the progression of Alzheimer disease
    Groussard, Mathilde
    Mauger, Caroline
    Platel, Herve
    GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT, 2013, 11 (01): : 99 - 109
  • [25] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline
    Evans, John Grimley
    Iakovidou, Vasso
    Tsolaki, Magda
    Holt, Francesca E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [26] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline S.
    Chong, Lee Yee
    Evans, John Grimley
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [27] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline S.
    Evans, John Grimley
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (04):
  • [28] Long-term effects of antidepressants on cognition in patients with Alzheimer's disease
    Caballero, J.
    Hitchcock, M.
    Beversdorf, D.
    Scharre, D.
    Nahata, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (06) : 593 - 598
  • [29] Long-term efficacy and safety of galantamine in patients with Alzheimer's disease treated for up to 4 years
    Burns, A
    Pirttila, T
    Gold, M
    Schwalen, S
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S382 - S382
  • [30] Amyloid β deposition and glucose metabolism on the long-term progression of preclinical Alzheimer's disease
    Hatashita, Shizuo
    Wakebe, Daichi
    FUTURE SCIENCE OA, 2019, 5 (03):
12345